Integration of PARP-inhibitors in ovarian cancer therapy

Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.

[1]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[2]  M. Morgan,et al.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.

[3]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[4]  N. Colombo,et al.  33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial , 2019, International Journal of Gynecological Cancer.

[5]  N. Colombo,et al.  Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. , 2019, Journal of Clinical Oncology.

[6]  B. Monk,et al.  Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[7]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[8]  J. Ledermann,et al.  Safety and dose modification for patients receiving niraparib , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Cesar M. Castro,et al.  Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. , 2017, Gynecologic oncology.

[10]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[11]  A. Tinker,et al.  Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial , 2017 .

[12]  James X. Sun,et al.  LBA40_PRARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC) , 2017 .

[13]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[14]  M. Moasser,et al.  Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors , 2017, Clinical Cancer Research.

[15]  T. Harding,et al.  Abstract 2475:In vitroandin vivoassessment of the mechanism of action of the PARP inhibitor rucaparib , 2017 .

[16]  K. Moore,et al.  Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer , 2017, OncoTargets and therapy.

[17]  A. Oza,et al.  Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study , 2017 .

[18]  David C. Smith,et al.  Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. , 2017, Cancer discovery.

[19]  A. Tinker,et al.  Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2 , 2017 .

[20]  B. Monk,et al.  Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). , 2017 .

[21]  A. Oza,et al.  A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors , 2017, Clinical Cancer Research.

[22]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[23]  D. Matei,et al.  Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. , 2016, The Lancet. Oncology.

[24]  G. Konecny,et al.  PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions , 2016, British Journal of Cancer.

[25]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[26]  B. Monk,et al.  gynaecological cancersA randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) , 2016 .

[27]  R. Finn,et al.  Abstract CT011: Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies , 2016 .

[28]  Ayala Hubert,et al.  Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. , 2016, Gynecologic oncology.

[29]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[31]  Alan Ashworth,et al.  Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. , 2014, Cancer research.

[32]  D. S. Pederson,et al.  Rules of engagement for base excision repair in chromatin , 2013, Journal of cellular physiology.

[33]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[34]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[35]  T. Helleday,et al.  Poly(ADP-ribose) Polymerase (PARP-1) in Homologous Recombination and as a Target for Cancer Therapy , 2005, Cell cycle.

[36]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[37]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.